Open AccessGonadotropin releasing hormone agonist treatment before hysterectomy for menorrhagia and uterine leiomyomas
Author(s) -
Vercellini Paolo,
Bocciolone Luca,
Colombo Alberto,
Vendola Nicoletta,
Meschia Mlchele,
Bolis Giorgio
Publication year - 1993
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016349309021115
Subject(s) - medicine , goserelin , hysterectomy , gonadotropin releasing hormone agonist , myoma , blood transfusion , leiomyoma , triptorelin , gynecology , agonist , surgery , gonadotropin releasing hormone , uterus , buserelin , hormone , receptor , cancer , breast cancer , luteinizing hormone
Objective . To investigate the effect of gonadotropin releasing hormone agonist (goserelin) treatment before hysterectomy for leiomyomata‐associated menorrhagia. Design . Prospective, comparative, nonrandomized study. Setting . A teaching hospital of Milano University. Patients . Anemic women requiring hysterectomy for myoma‐associated menorrhagia. Intervention . Six months' preoperative goserelin treatment (41 cases) or immediate surgery (92 controls). Main outcome measures . Abdominal/vaginal hysterectomy rate, number of transfusions, operating time, blood loss, complications, febrile morbidity, and days in hospital. Results . In the goserelin group mean hemoglobin rose (8.5 versus 13.3 g/dl) and mean uterine volume decreased (528 versus 251 ml). At preoperative pelvic exploration abdominal hysterectomy was indicated in 22 (54%) cases and 74 (80%) controls and vaginal hysterectomy in 19 (46%) and 18 (20%) (relative risk 3.6, 95% confidence interval 1.6 to 7.7; p = 0.001). No case required a transfusion whereas 51% of controls needed a total of 127 packed red cell units. Conclusions . In anemic women with menorrhagia and leiomyomas, gonadotropin releasing hormone agonist treatment before hysterectomy limited transfusion requirements and increased the vaginal procedure rate.